May 26, 2020
Impact of Baseline Dyskinesia on Safety and Efficacy of NOURIANZ® (istradefylline) in Patients with Parkinson's Disease Presented During "Virtual" European Academy of Neurology Meeting
May 13, 2020
Neurocrine Biosciences to Present Data from its Movement Disorder Portfolio on the American Academy of Neurology Science Highlights Platform
Apr 27, 2020
Neurocrine Biosciences Announces FDA Approval of Once-Daily ONGENTYS® (opicapone) as an Add-On Treatment for Patients with Parkinson's Disease Experiencing "Off" Episodes
Jan 17, 2020
Parkinson's Drug Market and Clinical Trial Insights Report, 2020-2025 - Availability, Dosage & Price Analysis on Levodopa/Carbidopa Therapeutics, Dopamine Agonist, MAO B Inhibitors, and More
Sep 25, 2019
Neuroscientist awarded $2.9M NIH grant to improve Parkinson's disease treatment
Sep 25, 2019
Intec Pharma Highlights Potential of Accordion Pill® Oral Drug Delivery Platform in Two Posters at International Congress of Parkinson's and Movement Disorder Society
Sep 23, 2019
AbbVie to Present New and Updated Data From 22 Abstracts, Including Two Late-Breaking Abstracts for ABBV-951 and DUODOPA® (levodopa/carbidopa intestinal gel), at the International Congress of Parkinson's Disease and Movement Disorders®
Sep 17, 2019
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®
Sep 16, 2019
Intec Pharma to Present Two Posters at International Congress of Parkinson's and Movement Disorder Society
Aug 27, 2019
FDA approves new add-on drug to treat off episodes in adults with Parkinson's disease
Jul 24, 2019
Parkinson's Disease Market Analysis, Market Size, Epidemiology, Leading Companies and Competitive Analysis by DelveInsight
Jul 22, 2019
Intec Pharma Reports Top-Line Phase 3 Trial Results of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients
Jul 10, 2019
Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease
Jun 25, 2019
Intec Pharma Announces Results from Earlier Phase 2 Clinical Trial of Accordion Pill-Carbidopa/Levodopa in Advanced Parkinson's Disease Patients Published in Parkinsonism and Related Disorders
Jun 19, 2019
Intec Pharma Announces Results From Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Were Presented at the XXIV World Congress on Parkinson's Disease and Related Disorders
Jun 11, 2019
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders
May 02, 2019
Intec Pharma's Data from Pharmacokinetic Study of AP-CD/LD 50/500 mg Dosed Three Times Daily Accepted for Presentation at the XXIV World Congress on Parkinson's Disease and Related Disorders
Apr 30, 2019
Neurocrine Biosciences to Present Data Analyses on INGREZZA® (valbenazine) and Opicapone at the 2019 American Academy of Neurology Annual Meeting
Apr 30, 2019
AbbVie to Present New and Updated Data of Investigational Medicines for Parkinson's Disease and Multiple Sclerosis at 2019 American Academy of Neurology Annual Meeting
Apr 30, 2019
Intec Pharma Reports Last Patient Last Visit in Pivotal Phase 3 Trial of Accordion Pill(TM) Carbidopa/Levodopa for the Treatment of Advanced Parkinson's Disease Patients